Titan Medical Inc (TMDIF)

[Frankestin]

Why did Dr. Advincula leave the SAB?
We need a logical answer! it happened a few days after this
https://ir.titanmedicalinc.com/news-events/press-releases/detail/337/titan-medical-announces-expansion-of-surgeon-advisory-board

https://books.google.it/books?id=BxtNEAAAQBAJ&pg=PA759&lpg=PA759&dq=Robotic+Surgery:+Advancements+and+Inflection+Points+in+the+Field+of+Gynecology&source=bl&ots=6pCmHVqPd3&sig=ACfU3U2NGtEA_nZOIE9pXyS1LggovgS1Xg&hl=it&sa=X&ved=2ahUKEwjBs57m5MT1AhUl7rsIHVnVCmgQ6AF6BAgDEAM#v=onepage&q=Robotic%20Surgery%3A%20Advancements%20and%20Inflection%20Points%20in%20the%20Field%20of%20Gynecology&f=false

https://www.jmig.org/action/showPdf?pii=S1553-4650%2818%2930601-0
What did he say about Sport?
Conclusions: While continued evolution of the prototype is needed, as well as validation in its ability to complete a surgical procedure, applica- tion of this new robot to successfully perform all the necessary tasks is demonstrated

https://www.columbiaobgyn.org/titan-medical-partners-columbia-university-medical-center-sport-feasibility-and-validation-studies are they still partners?

McNally 11 november:
And as they say, we’re working with our Surgeon Advisory Board, led by Dr. Arnold Advincula of Columbia University Medical Center, who is our medical advisor to develop the right sequence of curriculum, one to train for performing the IDE studies or clinical studies and then ultimately a program that can be rolled out upon marketing clearance to train an expanding group of surgeons. So that’s first question.

Second, with respect to license technologies, we will continually seek opportunities to license our IP and knowhow where it makes sense, as we did with the Medtronic development and license agreements where we’ve retained rights to all of that technology to implement in the Enos system. There may be other opportunities for us to out license, as well as licensing technology from other companies that would be complementary to what we have in terms of the Enos system.